Advertisement

‘ADVANCE’ (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer

Published:September 23, 2022DOI:https://doi.org/10.1016/j.jgo.2022.09.006

      Abstract

      Introduction

      Older adults with breast cancer receiving neo/adjuvant chemotherapy are at high risk for poor outcomes and are underrepresented in clinical trials. The ADVANCE (ADjuVANt Chemotherapy in the Elderly) trial evaluated the feasibility of two neo/adjuvant chemotherapy regimens in parallel-enrolling cohorts of older patients with human epidermal growth factor receptor 2-negative breast cancer: cohort 1—triple-negative; cohort 2—hormone receptor-positive.

      Materials and Methods

      Adults age ≥ 70 years with stage I-III breast cancer warranting neo/adjuvant chemotherapy were enrolled. Cohort 1 received weekly carboplatin (area under the curve 2) and weekly paclitaxel 80 mg/m2 for twelve weeks; cohort 2 received weekly paclitaxel 80 mg/m2 plus every-three-weekly cyclophosphamide 600 mg/m2 over twelve weeks. The primary study endpoint was feasibility, defined as ≥80% of patients receiving ≥80% of intended weeks/doses of therapy. All dose modifications were applied per clinician discretion.

      Results

      Forty women (n = 20 per cohort) were enrolled from March 25, 2019 through August 3, 2020 from three centers; 45% and 35% of patients in cohorts 1 and 2 were age > 75, respectively. Neither cohort achieved targeted thresholds for feasibility. In cohort 1, eight (40.0%) met feasibility (95% confidence interval [CI] = 19.1–63.9%), while ten (50.0%) met feasibility in cohort 2 (95% CI = 27.2–72.8). Neutropenia was the most common grade 3–4 toxicity (cohort 1—65%, cohort 2—55%). In cohort 1, 80% and 85% required ≥1 dose holds of carboplatin and/or paclitaxel, respectively. In cohort 2, 10% required dose hold(s) for cyclophosphamide and/or 65% for paclitaxel.

      Discussion

      In this pragmatic pilot examining chemotherapy regimens in older adults with breast cancer, neither regimen met target goals for feasibility. Developing efficacious and tolerable regimens for older patients with breast cancer who need chemotherapy remains an important goal.
      ClinicalTrials.gov Identifier: NCT03858322.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Smith B.D.
        • Smith G.L.
        • Hurria A.
        • Hortobagyi G.N.
        • Buchholz T.A.
        Future of cancer incidence in the United States: burdens upon an aging, changing nation.
        J Clin Oncol. 2009; 27: 2758-2765https://doi.org/10.1200/JCO.2008.20.8983
        • American Cancer Society
        Breast Cancer Facts & Figures.
        (Last accessed April 7, 2022)
        • Howlader N.
        • Altekruse S.F.
        • Li C.I.
        • Chen V.W.
        • Clarke C.A.
        • Ries L.A.
        • et al.
        US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
        J Natl Cancer Inst. 2014; 106: dju055https://doi.org/10.1093/jnci/dju055
        • Schonberg M.A.
        • Marcantonio E.R.
        • Li D.
        • Silliman R.A.
        • Ngo L.
        • McCarthy E.P.
        Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival.
        J Clin Oncol. 2010; 28: 2038-2045https://doi.org/10.1200/JCO.2009.25.9796
        • Schonberg M.A.
        • Marcantonio E.R.
        • Ngo L.
        • Li D.
        • Silliman R.A.
        • McCarthy E.P.
        Causes of death and relative survival of older women after a breast cancer diagnosis.
        J Clin Oncol. 2011; 29: 1570-1577https://doi.org/10.1200/JCO.2010.33.0472
        • Satariano W.A.
        • Ragland D.R.
        The effect of comorbidity on 3-year survival of women with primary breast cancer.
        Ann Intern Med. 1994; 120: 104-110
        • Yancik R.
        • Wesley M.N.
        • Ries L.A.
        • Havlik R.J.
        • Edwards B.K.
        • Yates J.W.
        Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older.
        JAMA. 2001; 285 (doi:joc00907 [pii]): 885-892
        • Smith B.D.
        • Jiang J.
        • McLaughlin S.S.
        • Hurria A.
        • Smith G.L.
        • Giordano S.H.
        • et al.
        Improvement in breast cancer outcomes over time: are older women missing out?.
        J Clin Oncol. 2011; 29: 4647-4653https://doi.org/10.1200/JCO.2011.35.8408
        • Freedman R.A.
        • Keating N.L.
        • Lin N.U.
        • Winer E.P.
        • Vaz-Luis I.
        • Lii J.
        • et al.
        Breast cancer-specific survival by age: worse outcomes for the oldest patients.
        Cancer. 2018; 124: 2184-2191https://doi.org/10.1002/cncr.31308
        • Griggs J.J.
        • Culakova E.
        • Sorbero M.E.
        • Poniewierski M.S.
        • Wolff D.A.
        • Crawford J.
        • et al.
        Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.
        J Clin Oncol. 2007; 25: 2522-2527
        • Vaz-Luis I.
        • Keating N.L.
        • Lin N.U.
        • Lii H.
        • Winer E.P.
        • Freedman R.A.
        Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study.
        J Clin Oncol. 2014; 32: 927-934https://doi.org/10.1200/JCO.2013.51.1261
        • Freedman R.A.
        • Vaz-Luis I.
        • Barry W.T.
        • Lii H.
        • Lin N.U.
        • Winer E.P.
        • et al.
        Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy.
        Breast Cancer Res Treat. 2014; 145: 491-501https://doi.org/10.1007/s10549-014-2968-9
        • Schreiber A.R.
        • Kagihara J.
        • Eguchi M.
        • Kabos P.
        • Fisher C.M.
        • Meyer E.
        • et al.
        Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study.
        Breast Cancer Res Treat. 2022; 191: 389-399https://doi.org/10.1007/s10549-021-06424-z
        • Reeder-Hayes K.E.
        • Meyer A.M.
        • Hinton S.P.
        • Meng K.
        • Carey L.A.
        • Dusetzina S.B.
        Comparative toxicity and effectiveness of Trastuzumab-based chemotherapy regimens in older women with early-stage breast cancer.
        J Clin Oncol. 2017; 35: 3298-3305https://doi.org/10.1200/JCO.2016.71.4345
        • Magnuson A.
        • Sedrak M.S.
        • Gross C.P.
        • Tew W.P.
        • Klepin H.D.
        • Wildes T.M.
        • et al.
        Development and validation of a risk tool for predicting severe toxicity in older adults receiving chemotherapy for early-stage breast cancer.
        J Clin Oncol. 2021; 39: 608-618https://doi.org/10.1200/JCO.20.02063
        • Barcenas C.H.
        • Niu J.
        • Zhang N.
        • Zhang Y.
        • Buchholz T.A.
        • Elting L.S.
        • et al.
        Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.
        J Clin Oncol. 2014; 32: 2010-2017https://doi.org/10.1200/JCO.2013.49.3676
        • Biganzoli L.
        • Battisti N.M.L.
        • Wildiers H.
        • McCartney A.
        • Colloca G.
        • Kunkler I.H.
        • et al.
        Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG).
        Lancet Oncol. 2021; 22: e327-e340https://doi.org/10.1016/s1470-2045(20)30741-5
        • Brouwers B.
        • Hatse S.
        • Dal Lago L.
        • Neven P.
        • Vuylsteke P.
        • Dalmasso B.
        • et al.
        The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters.
        Oncotarget. 2016; 7: 29977-29988https://doi.org/10.18632/oncotarget.8796
        • Muss H.B.
        • Berry D.A.
        • Cirrincione C.T.
        • Theodoulou M.
        • Mauer A.M.
        • Kornblith A.B.
        • et al.
        Adjuvant chemotherapy in older women with early-stage breast cancer.
        N Engl J Med. 2009; 360: 2055-2065https://doi.org/10.1056/NEJMoa0810266
        • von Minckwitz G.
        • Reimer T.
        • Potenberg J.
        • Conrad B.
        • Schurer U.
        • Eldtmann H.
        • et al.
        Abstract S3-04. The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer.
        Cancer Res. 2015; 75: S3-04
        • Jones S.
        • Holmes F.A.
        • O’Shaughnessy J.
        • Blum J.L.
        • Vukelja S.J.
        • McIntyre K.J.
        • et al.
        Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735.
        J Clin Oncol. 2009; 27: 1177-1183https://doi.org/10.1200/JCO.2008.18.4028
        • Jones S.E.
        • Erban J.
        • Overmoyer B.
        • Budd G.T.
        • Hutchins L.
        • Lower E.
        • et al.
        Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
        J Clin Oncol. 2005; 23: 5542-5551https://doi.org/10.1200/JCO.2005.02.027
        • Wolff A.C.
        • Hammond M.E.H.
        • Allison K.H.
        • Harvey B.E.
        • Mangu P.B.
        • Bartlett J.M.S.
        • et al.
        Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
        J Clin Oncol. 2018; 36: 2105-2122https://doi.org/10.1200/JCO.2018.77.8738
        • von Minckwitz G.
        • Schneeweiss A.
        • Loibl S.
        • Salat C.
        • Denkert C.
        • Rezai M.
        • et al.
        Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
        Lancet Oncol. 2014; 15: 747-756https://doi.org/10.1016/S1470-2045(14)70160-3
        • Sikov W.M.
        • Berry D.A.
        • Perou C.M.
        • Singh B.
        • Cirrincione C.T.
        • Tolaney S.M.
        • et al.
        Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
        J Clin Oncol. 2015; 33: 13-21https://doi.org/10.1200/jco.2014.57.0572
        • Alba E.
        • Chacon J.I.
        • Lluch A.
        • Anton A.
        • Estevez L.
        • Cirauqui B.
        • et al.
        A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study.
        Breast Cancer Res Treat. 2012; 136: 487-493https://doi.org/10.1007/s10549-012-2100-y
        • Sharma P.
        • Lopez-Tarruella S.
        • Garcia-Saenz J.A.
        • Ward C.
        • Connor C.S.
        • Gomez H.L.
        • et al.
        Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts.
        Clin Cancer Res. 2017; 23: 649-657https://doi.org/10.1158/1078-0432.CCR-16-0162
        • Huang L.
        • Chen S.
        • Yao L.
        • Liu G.
        • Wu J.
        • Shao Z.
        Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.
        Int J Nanomedicine. 2015; 10: 1969-1975https://doi.org/10.2147/IJN.S77000
        • Vernieri C.
        • Milano M.
        • Mennitto A.
        • Maggi C.
        • Ferrari B.
        • Rinaldi L.
        • et al.
        Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
        Breast Cancer Res Treat. 2017; 165: 365-373https://doi.org/10.1007/s10549-017-4336-z
        • Quoix E.
        • Zalcman G.
        • Oster J.P.
        • Westeel V.
        • Pichon E.
        • Lavole A.
        • et al.
        Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
        Lancet. 2011; 378: 1079-1088https://doi.org/10.1016/S0140-6736(11)60780-0
        • Socinski M.A.
        • Okamoto I.
        • Hon J.K.
        • Hirsh V.
        • Dakhil S.R.
        • Page R.D.
        • et al.
        Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
        Ann Oncol. 2013; 24: 2390-2396https://doi.org/10.1093/annonc/mdt235
        • Maemondo M.
        • Inoue A.
        • Sugawara S.
        • Harada T.
        • Minegishi Y.
        • Usui K.
        • et al.
        Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: North Japan Lung Cancer Group Trial 0801.
        Oncologist. 2014; 19: 352-353https://doi.org/10.1634/theoncologist.2013-0411
        • Yu K.D.
        • Ye F.G.
        • He M.
        • Fan L.
        • Ma D.
        • Mo M.
        • et al.
        Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial.
        JAMA Oncol. 2020; 6: 1390-1396https://doi.org/10.1001/jamaoncol.2020.2965
        • Lichtman S.M.
        • Hurria A.
        • Cirrincione C.T.
        • Seidman A.D.
        • Winer E.
        • Hudis C.
        • et al.
        Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840.
        Ann Oncol. 2012; 23: 632-638https://doi.org/10.1093/annonc/mdr297
        • Seidman A.D.
        • Berry D.
        • Cirrincione C.
        • Harris L.
        • Muss H.
        • Marcom P.K.
        • et al.
        Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
        J Clin Oncol. 2008; 26: 1642-1649https://doi.org/10.1200/JCO.2007.11.6699
        • Sparano J.A.
        • Zhao F.
        • Martino S.
        • Ligibel J.A.
        • Perez E.A.
        • Saphner T.
        • et al.
        Long-term follow-up of the E1199 phase III trial evaluating the role of Taxane and schedule in operable breast cancer.
        J Clin Oncol. 2015; 33: 2353-2360https://doi.org/10.1200/jco.2015.60.9271
        • Sparano J.A.
        • Wang M.
        • Martino S.
        • Jones V.
        • Perez E.A.
        • Saphner T.
        • et al.
        Weekly paclitaxel in the adjuvant treatment of breast cancer.
        N Engl J Med. 2008; 358: 1663-1671https://doi.org/10.1056/NEJMoa0707056
        • Citron M.L.
        • Berry D.A.
        • Cirrincione C.
        • Hudis C.
        • Winer E.P.
        • Gradishar W.J.
        • et al.
        Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and leukemia group B trial 9741.
        J Clin Oncol. 2003; 21: 1431-1439https://doi.org/10.1200/JCO.2003.09.081
        • Masuda N.
        • Nakayama T.
        • Yamamura J.
        • Kamigaki S.
        • Taguchi T.
        • Hatta M.
        • et al.
        Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer.
        Cancer Chemother Pharmacol. 2010; 66: 89-94https://doi.org/10.1007/s00280-009-1137-z
        • Kutomi G.
        • Ohmura T.
        • Satomi F.
        • Maeda H.
        • Shima H.
        • Kameshima H.
        • et al.
        A phase I study of combination therapy with nanoparticle albumin-bound paclitaxel and cyclophosphamide in patients with metastatic or recurrent breast cancer.
        Int J Clin Oncol. 2015; 20: 474-479https://doi.org/10.1007/s10147-014-0725-z
        • Pagani O.
        • Sessa C.
        • Martinelli G.
        • Cerny T.
        • de Jong J.
        • Goldhirsch A.
        • et al.
        Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer.
        Ann Oncol. 1997; 8: 655-661
      1. Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery.
        • Hurria A.
        • Cirrincione C.T.
        • Muss H.B.
        • Kornblith A.B.
        • Barry W.
        • Artz A.S.
        • et al.
        Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401.
        J Clin Oncol. 2011; 29: 1290-1296https://doi.org/10.1200/JCO.2010.30.6985
        • Hurria A.
        • Lichtman S.M.
        • Gardes J.
        • Li D.
        • Limaye S.
        • Patil S.
        • et al.
        Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice.
        J Am Geriatr Soc. 2007; 55: 1604-1608https://doi.org/10.1111/j.1532-5415.2007.01367.x
        • Hurria A.
        • Lachs M.S.
        • Cohen H.J.
        • Muss H.B.
        • Kornblith A.B.
        Geriatric assessment for oncologists: rationale and future directions.
        Crit Rev Oncol Hematol. 2006; 59: 211-217https://doi.org/10.1016/j.critrevonc.2006.03.007
        • Hurria A.
        • Gupta S.
        • Zauderer M.
        • Zuckerman E.L.
        • Cohen H.J.
        • Muss H.
        • et al.
        Developing a cancer-specific geriatric assessment: a feasibility study.
        Cancer. 2005; 104: 1998-2005https://doi.org/10.1002/cncr.21422
        • Rockwood K.
        • Mitnitski A.
        Frailty in relation to the accumulation of deficits.
        J Gerontol A Biol Sci Med Sci. 2007; 62: 722-727https://doi.org/10.1093/gerona/62.7.722
      2. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
        (Last accessed March 18, 2022)
        • Colleoni M.
        • Price K.
        • Castiglione-Gertsch M.
        • Goldhirsch A.
        • Coates A.
        • Lindtner J.
        • et al.
        Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.
        Eur J Cancer. 1998; 34: 1693-1700https://doi.org/10.1016/s0959-8049(98)00209-3
        • Stewart A.L.
        • Hays R.D.
        • Wells K.B.
        • Rogers W.H.
        • Spritzer K.L.
        • Greenfield S.
        Long-term functioning and well-being outcomes associated with physical activity and exercise in patients with chronic conditions in the medical outcomes study.
        J Clin Epidemiol. 1994; 47: 719-730https://doi.org/10.1016/0895-4356(94)90169-4
        • Fillenbaum G.G.
        • Smyer M.A.
        The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire.
        J Gerontol. 1981; 36: 428-434https://doi.org/10.1093/geronj/36.4.428
        • Loprinzi C.L.
        • Laurie J.A.
        • Wieand H.S.
        • Krook J.E.
        • Novotny P.J.
        • Kugler J.W.
        • et al.
        Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group.
        J Clin Oncol. 1994; 12: 601-607https://doi.org/10.1200/JCO.1994.12.3.601
        • Podsiadlo D.
        • Richardson S.
        The timed “Up & Go”: a test of basic functional mobility for frail elderly persons.
        J Am Geriatr Soc. 1991; 39: 142-148https://doi.org/10.1111/j.1532-5415.1991.tb01616.x
        • Stewart A.L.
        • Ware Jr., J.E.
        Measuring functioning and well-being: The medical outcomes study approach.
        Duke University Press, Durham, NC1992
        • Sherbourne C.D.
        • Stewart A.L.
        The MOS social support survey.
        Soc Sci Med. 1991; 32: 705-714
        • Katzman R.
        • Brown T.
        • Fuld P.
        • Peck A.
        • Schechter R.
        • Schimmel H.
        Validation of a short orientation-memory-concentration test of cognitive impairment.
        Am J Psychiatry. 1983; 140: 734-739https://doi.org/10.1176/ajp.140.6.734
        • Sharma P.
        • Kimler B.F.
        • O’Dea A.
        • Nye L.
        • Wang Y.Y.
        • Yoder R.
        • et al.
        Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP).
        Clin Cancer Res. 2021; 27: 975-982https://doi.org/10.1158/1078-0432.CCR-20-3646
        • Sharma P.
        • Lopez-Tarruella S.
        • Garcia-Saenz J.A.
        • Khan Q.J.
        • Gomez H.L.
        • Prat A.
        • et al.
        Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel.
        Clin Cancer Res. 2018; 24: 5820-5829https://doi.org/10.1158/1078-0432.CCR-18-0585
        • Yardley D.A.
        • Coleman R.
        • Conte P.
        • Cortes J.
        • Brufsky A.
        • Shtivelband M.
        • et al.
        Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
        Ann Oncol. 2018; 29: 1763-1770https://doi.org/10.1093/annonc/mdy201
        • Yuan Y.
        • Lee J.S.
        • Yost S.E.
        • Li S.M.
        • Frankel P.H.
        • Ruel C.
        • et al.
        Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with triple-negative breast cancer.
        Oncologist. 2021; 26: e382-e393https://doi.org/10.1002/onco.13574
        • Laurent M.
        • Paillaud E.
        • Tournigand C.
        • Caillet P.
        • Le Thuaut A.
        • Lagrange J.L.
        • et al.
        Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study.
        Oncologist. 2014; 19: 275-282https://doi.org/10.1634/theoncologist.2013-0351
        • Sud S.
        • Lai P.
        • Zhang T.
        • Clemons M.
        • Wheatley-Price P.
        Chemotherapy in the oldest old: the feasibility of delivering cytotoxic therapy to patients 80 years old and older.
        J Geriatr Oncol. 2015; 6: 395-400https://doi.org/10.1016/j.jgo.2015.07.002
        • Shulman L.N.
        • Berry D.A.
        • Cirrincione C.T.
        • Becker H.P.
        • Perez E.A.
        • O’Regan R.
        • et al.
        Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
        J Clin Oncol. 2014; 32: 2311-2317https://doi.org/10.1200/JCO.2013.53.7142
        • Schmid P.
        • Cortes J.
        • Pusztai L.
        • McArthur H.
        • Kummel S.
        • Bergh J.
        • et al.
        Pembrolizumab for early triple-negative breast Cancer.
        N Engl J Med. 2020; 382: 810-821https://doi.org/10.1056/NEJMoa1910549
        • Schmid P.
        • Cortes J.
        • Dent R.
        • Pusztai L.
        • McArthur H.
        • Kummel S.
        • et al.
        Event-free survival with Pembrolizumab in early triple-negative breast Cancer.
        N Engl J Med. 2022; 386: 556-567https://doi.org/10.1056/NEJMoa2112651